Elaine Quilici

In episode 104, Susanne Schaffert, president of Novartis Oncology, discusses her career journey, which has combined both a passion for the arts and science, and how she believes the two can work together in pharma.

A look at the renewed efforts of biopharma companies in exploring age-old substances to treat mental health conditions and more, minus the negative effects.

For pharma teams, reaping the talent benefits requires skillful oversight.

Prior experiences in pharma and handling of opioid epidemic offer valuable lessons.

In episode 103, Robert Clarke, CEO and co-founder of Kinaset Therapeutics, talks about developing inhaled therapies to fight asthma and COPD, which is especially relevant as COVID-19 poses significant problems for sufferers.

In episode 102, Mike Devoy, chief medical officer of Bayer, also executive vice president of medical affairs and pharmacovigilance for Bayer’s Pharmaceuticals Division, discusses how innovation, including the digitalization of healthcare delivery, and breakthrough technologies can help people make the most out of the longer lives they’re living today.

Addressing whole employee is as important as treating whole patient.

Assessing the value of industry.

In episode 101, Bruno Larvol, CEO and founder of Larvol, discusses how he is invested in the digital world, both personally and professionally, and the impact it can have.

Our milestone 100th episode includes Lisa Henderson, group editorial director; Julian Upton, European and online editor; Fran Pollaro, senior editor; and Andy Studna, associate editor, discussing industry trends in areas such as Chinese biotech, corporate branding, psychedelic medicines, and market access barriers.

Oncology and rare disease are ready to reap the benefits of COVID drug development.

Growing evidence supports psychoactive substances can successfully treat mental issues.

Questions grow over adding titles to the biopharma C-suite.

Bill Sibold, executive vice president and head of Sanofi Genzyme, talks about his work in specialty care over the past 10 years and what makes it unique.

Giacomo Chiesi, Head of Global Rare Diseases at the Chiesi Group, discusses what it has been like growing up around pharma, and how he’s turned a family passion into his own dedicated career path.

It’s time to see how you’re doing with putting words into action.

Looking Back at 2018–2021.

Mike Ward, Global Head of Thought Leadership in the Decision Resources Group at Clarivate, goes behind the numbers of our 2022 pipeline report and provides some interesting insights from the report provided by his company.

Tim Whitten, CEO and president of Taiho Oncology, discusses how innovative thinking—from developing new therapies to creating a podcast for employees during COVID—has played an important role in his professional journey.

Jeff Stoll, US Life Sciences Strategy Leader at KPM, talks about some of the highlights from KPMG’s recent Global Pharma CEO Outlook report.

How an increased focus on people has helped companies survive the pandemic.

Moderna Chief Medical Officer Paul Burton looks to build on culture of innovation and speed to advance COVID-19 vaccine and develop new therapies based on its novel mRNA platform, spreading hope to patients around the world.

Building and maintaining relationships can lead to better decisions.

Amie Krause, Senior Vice President and Chief People Officer, and Kristin Yarema, Chief Commercial Officer, of Atara Biotherapeutics, talk about gender diversity in the c-suite and how that can benefit a company both internally and externally.

Michael Petroutsas, Senior Vice President and Head of GSK’s US Oncology Business Unit, talks about how his background has taught him the importance of connecting with patients on their level and how he brings that mentality to GSK.

Unconventional collaborations between biopharma and tech are starting to take off.

Imvax CEO John Furey taps into tried-and-true powers of hope and clarity as he moves the clinical stage biotech from single program to platform company.

Soft skills are needed to round out the hard numbers.

Tom McCourt, CEO of Ironwood Pharmaceuticals, talks about his 30-plus years in the gastrointestinal space, including his experiences bringing top GI medicines Prilosec, Nexium, Entocort, Zelnorm, and Linzess to market.

Dr. Michael Henderson, chief business officer of BridgeBio Pharma, and one of Pharm Exec’s 2021 Emerging Pharma Leaders, discusses how his company goes beyond the traditional “hand off” approach between academia and industry, and looks to partner with institutions early on to fill important voids in drug development.